PTH/PTHrP analogues as osteoanabolic treatment in patients with osteoporosis.

Teriparatide (TPTD) and abaloparatide (ABL) are osteoanabolic drugs belonging to the group of parathyroid hormone analogues and parathyroid hormone-related protein analogues, respectively. Both drugs have been shown to be effective and safe in the treatment of postmenopausal osteoporosis (PMO), reducing the risk of vertebral and nonvertebral fractures and improving bone microarchitecture, especially in patients with severe osteoporosis. For this reason, guidelines recommend their use as first-line treatment for patients at very high risk of fracture. Although TPTD and ABL act on the same receptor, PTHR1, they trigger a different signaling response, which explains why their effects on bone remodeling are also different, with similar osteoanabolic action, but with less stimulation of resorption by ABL, which confers a greater benefit on cortical bone.